Welcome to CiTI: a multi-disciplinary Centre for Inflammation and Therapeutic Innovation.
Located in the heart of the City of London, the new multi-disciplinary Centre for Inflammation and Therapeutic Innovation (CiTI) at Queen Mary University of London (QMUL) presents a unique opportunity for a strategic partnership aimed at exploring, endorsing, developing and testing innovative strategies for anti-inflammatory therapies with a two-way bench to bedside approach.
CiTI stems from the world-class track record of the William Harvey Research Institute in inflammation research, bringing together many sections of the School of Medicine and Dentistry, and the College. The rationale behind the CiTI is to position the science of inflammation as the common thread of several high penetrance and debilitating pathologies and focus on therapeutic innovation as its unique angle cut. CiTI brings together the vast and multi-cultural patient population of north-east London and QMUL's strengths in bioengineering, biomedical and medical sciences with translational research.
The overall aim of this multi-dimensional collaborative venture is to accelerate the application of research discoveries into improved patient care. CiTI will capitalise on QMUL technological expertise and innovations to identify new therapeutic targets, interventions, diagnostics, prevention strategies and stratified medicine in the context of defined inflammatory disorders.
Our Mission statement: Linking basic and clinical excellence in inflammation sciences and technological knowledge to achieve innovative translational research, training and clinical care for the benefit of patients and society at large.
- Sussan Nourshargh and Antal Rot publish paper on chemokines in Immunity.
- CITI symposium 2018, the chronic inflammation path to cancer and obesity.
- Read more about our Arthritis in the CiTI public engagement event held in June 2018. We have also written a blog about the event for #ArthritisAwarenessWeek.